Elevated Platelet Count as Prognostic Factor in Colorectal Cancer With Synchronous Liver Metastases

NCT03717519 | Completed

• 1 other identifier: CHIR CR
• Study Type: observational
• Target: 196
• Locations: 1 country
• Sites: 1

Brief Summary

Colorectal cancer (CRC) is the third most common malignancy worldwide and is often metastatic at diagnosis. Despite progresses in surgical techniques and the introduction of novel chemotherapy regimens, many patients still suffer from a poor prognosis. It is therefore of utmost importance to identify prognostic markers that may improve selection of patients. In recent years several studies demonstrated that preoperative blood tests as platelet count or neuthophil-to-lymphocyte ratio could be prognostic factors in CRC as well as other malignancies. The aim of this study was to evaluate the role of preoperative platelet count (PC) in patients with synchronous colorectal liver metastases.

Conditions

Colorectal Cancer; Colorectal Carcinoma; Stage IV Colon Cancer

Keywords

platelets; thrombocytosis; prognosis

Outcome Measures

Primary Outcomes (1)

• Overall survival

  correlation between high PC and overall survival

  5 years

Secondary Outcomes (1)

• Clinic-pathological variables

  30 days

Study Arms (1)

s-CRLM

Patients with synchronous colorectal liver metastases who underwent surgical resection

Diagnostic Test: Measurement of platelet count at diagnosis

Interventions

Measurement of platelet count at diagnosis DIAGNOSTIC_TEST

Blood samples were drawn by expert phlebotomists in vacuum blood tubes containing K2-EDTA (Terumo Europe NV, Leuven, Belgium). The complete blood cell count (CBC) was performed using Advia 2120 (Siemens Healthcare Diagnostics, Tarrytown NY, USA). The local reference range for platelets was 150-400 x 109/L. The same analyser was used throughout the study period, and the quality and reproducibility of test results was validated by data of both internal quality control and external quality assessment

s-CRLM

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients who underwent surgery for colorectal cancer with synchronous liver metastases in the study period, and who fulfilled the inclusion criteria.

You may qualify if:

• Colorectal cancer with synchronous liver metastases
• Possibility to retrieve pre-operative platelet count
• Age of 18 years or older
• Availabilty of clinical-pathological data
• Minimum follow up of 12 months

You may not qualify if:

• None

Sponsors & Collaborators

• Azienda Ospedaliera Universitaria Integrata Verona: lead

Study Sites (1)

Chirurgia Generale ed Epatobiliare, Policlinico GB Rossi

Verona, 37134, Italy

Location

Related Publications (3)

• Pedrazzani C, Mantovani G, Fernandes E, Bagante F, Luca Salvagno G, Surci N, Campagnaro T, Ruzzenente A, Danese E, Lippi G, Guglielmi A. Assessment of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and platelet count as predictors of long-term outcome after R0 resection for colorectal cancer. Sci Rep. 2017 May 4;7(1):1494. doi: 10.1038/s41598-017-01652-0.

  PMID: 28473700 BACKGROUND

• Wan S, Lai Y, Myers RE, Li B, Hyslop T, London J, Chatterjee D, Palazzo JP, Burkart AL, Zhang K, Xing J, Yang H. Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. J Gastrointest Cancer. 2013 Sep;44(3):293-304. doi: 10.1007/s12029-013-9491-9.

  PMID: 23549858 BACKGROUND

• Baranyai Z, Krzystanek M, Josa V, Dede K, Agoston E, Szasz AM, Sinko D, Szarvas V, Salamon F, Eklund AC, Szallasi Z, Jakab F. The comparison of thrombocytosis and platelet-lymphocyte ratio as potential prognostic markers in colorectal cancer. Thromb Haemost. 2014 Mar 3;111(3):483-90. doi: 10.1160/TH13-08-0632. Epub 2013 Nov 28.

  PMID: 24285160 BACKGROUND

MeSH Terms

Conditions

Colorectal Neoplasms; Colonic Neoplasms; Thrombocytosis

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Blood Platelet Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Myeloproliferative Disorders; Bone Marrow Diseases

Study Officials

• Corrado Pedrazzani, MD

  Azienda Ospedaliera Universitaria Integrata Verona

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: October 22, 2018
• First Posted: October 24, 2018
• Study Start: January 1, 2018
• Primary Completion: May 1, 2018
• Study Completion: September 1, 2018
• Last Updated: July 20, 2023

Record last verified: 2023-07

Locations

IT (1)